Abstract Pregnant women undergoing prenatal genetic testing should receive genetic counseling so they can make informed decisions. We examined the current state of providing genetic counseling in Japan to pregnant women before they elected amniocentesis for prenatal diagnosis of chromosome abnormalities and after test results were completed, and explored the opportunity for expanding access to certified genetic counselors (CGC) at clinical practices offering amniocentesis. An anonymous survey was mailed to the 298 hospitals that referred amniotic fluid specimens to LabCorp Japan in 2009. Most genetic counseling was provided by the obstetrician alone; 73.8 % (76/103) of preamniocentesis, 82.5 % (85/103) if normal results, and 49.4 % (44/89) if abnormal results. Respondents spent limited time in genetic counseling; 57.3 % spent <10 min for pre-amniocentesis, 88.3 % spent <10 min for normal results, and 54.0 % spent <20 min for abnormal results. While 45.8 % indicated that CGC do not have an essential role in clinical practice, responses that supported employment of CGC were more likely to come from hospitals that submitted more than ten specimens annually (p<0.0001), university hospitals (p<0.0001), and MD geneticists (p=0.020). Currently, there is limited genetic counseling available in Japan. This indicates there are opportunities for the employment of CGC to improve the quality of genetic counseling.
Introduction
Since the early 1970s, amniocentesis for prenatal diagnosis of chromosome abnormalities was offered to women considered to be at increased risk of carrying a fetus with Down syndrome or other chromosomal abnormalities. Prenatal maternal serum screening (MSS) provided individualized risk estimates for Down syndrome and trisomy 18 that could be used to decide whether or not to proceed with invasive diagnostic testing. In Japan, based on the population distribution of maternal age and assuming no prenatal diagnosis or termination of pregnancy, the projected frequency of Down syndrome was 1.79 per 1,000 (or 1/566) live births in 2006 (Kajii 2008) . Although both invasive diagnostic testing and prenatal MSS are performed in Japan, the uptake rate of each test is extremely low compared with other advanced countries; less than 2 % of all pregnant women in Japan received prenatal MSS, and less than 2 % had invasive diagnostic testing (Sasaki et al. 2011) .
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including the Japan Society of Human Genetics (JSHG) and the Japanese Society for Genetic Counseling (JSGC) stated in their guidelines that advanced maternal age (AMA) is an appropriate indication for referral for prenatal diagnostic testing (JSOG 2007; GMRS 2003) . However, the guidelines do not require physicians to inform AMA pregnant women of diagnostic testing options. Prenatal MSS is not commonly offered to women based on the 1999 statement by the Expert Committee on Prenatal Diagnosis of the Sciences Council for Evaluating Advanced Medical Techniques of Japan (1999) . This stated that physicians were not required to give information about MSS to pregnant women and should not even recommend this test. In 2011, the JSOG updated their earlier position regarding MSS indicating that obstetricians can offer the option of MSS and that discussion should include appropriate and sufficient genetic counseling (JSOG 2011) .
Another deterrent to pregnant women receiving prenatal diagnosis in Japan may be related to issues surrounding abortion which is not permitted legally for fetal abnormalities. Based on the statement from the Ministry of Health, Labor and Welfare in 1990, artificial abortions before 22 weeks gestation are permitted for certain indications. The maternal health protection law from 2011 permits artificial abortions with the following two conditions; 1) if maternal health may be seriously affected by continuation of the pregnancy or childbirth due to medical or economic problems, and 2) conception from rape. Although artificial abortions because of fetal abnormalities are performed with maternal economic or health problems given as the reason, many people in Japan believe that artificial abortions are unethical even if a fetus has serious abnormalities (Sasaki et al. 2011) .
The National Society of Genetic Counselors (NSGC) and the Japanese Association of Medical Sciences (JAMS) state that genetic counseling is a process to help people understand and adapt to the medical, psychological and familial implications of genetic contributions to disease (NSGC 2006; JAMS 2011) . Genetic counseling regarding amniocentesis for fetal chromosome analysis should provide accurate and clear information about the risks, benefits and limitations of testing that allows pregnant women to make informed decisions about testing. Genetic counselors have a unique skill set that allows them to play a role in both providing information about prenatal testing and helping patients understand how this information applies to their own experiences and concerns (Farrelly et al. 2012 ). Thus, their interactions with patients can be especially helpful when it occurs before prenatal testing by facilitating informed decision making (Farrelly et al. 2012) . In Japan, in order to improve the use of medical geneticists who get involved in clinical genetics, the Japanese Board of Medical Genetics was established in 1991, and a total of 968 clinical geneticists were qualified by 2012 (Japanese Board of Medical Genetics 2012). As of November 2012, JSGC and the JSHG have certified 139 genetic counselors who are not medical doctors since the certification system was established in 2004 (Japanese Board of Certified Genetic Counselors 2012). According to one survey, 52.7 % of certified genetic counselors (CGC) worked at hospitals, and this was followed by work at a company (14.9 %), education or research institution (13.5 %) and students of doctoral courses (13.5 %). Among CGC who worked at hospitals, 35.8 % were employed as CGC, and the rest of them (64.2 %) were employed as healthcare professionals such as nurses and midwives (Yamanouchi et al. 2010; Yamanouchi, personal communication, February 4, 2013) .
This study explored the current state in Japan of providing genetic counseling to pregnant women before electing amniocentesis for prenatal diagnosis of chromosome abnormalities and after test results were completed, and also looked at the opportunity for expanding access to CGC at clinical practices offering amniocentesis.
Methods
A self-administered anonymous survey was mailed to the 298 hospitals and private clinics that are LabCorp Japan clients which referred amniotic fluid specimens for fetal chromosome analysis in 2009. The address of each hospital and the name of person in charge of prenatal testing were obtained from customer registration data at LabCorp Japan. LabCorp Japan is a Laboratory Corporation of America Holdings company and offers testing services for reproductive and genetic medicine, specifically prenatal testing. Chorionic villi sampling (CVS) was not included as this is rarely performed in Japan. This study was approved by the Ethical Committee of Kyoto University.
Data Collection
The survey instrument (Appendix 1) was developed by the investigator, based on preliminary conversations with multiple obstetricians who provided genetic counseling for pregnant women before they elected amniocentesis for prenatal diagnosis of chromosome abnormalities and after test results were completed. Multiple drafts of the content of the questionnaire were reviewed by medical geneticists, CGC, and students enrolled in a Master's level genetic counseling program.
The instructions specified that the survey should be completed by the person most familiar with the current process for providing information regarding amniocentesis for prenatal diagnosis and results of fetal chromosome analysis. The survey asked a total of 39 questions: five related to practice demographics; seven to the characteristics of the hospital; five about genetic counseling before electing amniocentesis for prenatal diagnosis of chromosome abnormalities; 13 about the genetic counseling after test results were completed; two about the understanding of two relevant professional guidelines (Guidelines for Prenatal Diagnosis for Congenital Fetal Abnormalities (JSOG 2007) and Guidelines for Genetic Testing (GMRS 2003)); five related to the employment opportunity for CGC at clinical practices offering amniocentesis for prenatal diagnosis; and two about opinions of the employer providing prenatal diagnostic testing. Respondents were asked to complete the survey and return their completed, anonymous responses in an enclosed, stamped envelope. Collection of survey responses was closed in August 2010.
Data Analysis
Responses were analyzed by SPSS version 11.5 software using descriptive analysis, chi-square test as a univariate analysis, and logistic regression as a multivariate analysis. In this study, a p value <0.05 was considered statistically significant.
Results
Of the 298 mailed surveys, 37.2 % (110) were returned with a valid response rate of 93.6 % (103/110). Baseline data for these respondents are given in Table 1 . The largest proportion of practice settings was private clinics, 47.6 %. Approximately 75 % of respondents were from 40 to 59 years of age. The annual number of amniocenteses performed at the facilities ranged from less than 10 to greater than 100, with 50.5 % submitting less than ten specimens annually. Over 80 % of respondents were obstetricians not certified as MD geneticists. A total of 16 respondents (15.6 %) were MD geneticists; 15 of these were obstetricians certified as MD geneticists. There were no CGC among the respondents. Over half of the hospitals had more than three full-time obstetricians; 24.3 % had only one obstetrician.
Among the 103 surveys with valid responses, 89 respondents (86.4 %) answered that they had provided genetic counseling prior to amniocentesis and, when results became available for both normal and abnormal results. The remaining 14 respondents had experience with providing genetic counseling prior to amniocentesis and afterwards only if there were normal results. Regarding the individual(s) providing genetic counseling, the data revealed that preamniocentesis genetic counseling was usually provided by the obstetrician alone (73.8 %), by MD geneticists (18.4 %), including obstetricians certified as MD geneticists (12.6 %) and MD geneticists with other specialties (5.8 %), and by an obstetrician and nurse/midwife (7.8 %) ( Table 2 ). After results became available, normal fetal chromosome results were most frequently communicated by the obstetrician alone (82.5 %), by MD geneticists in 15.5 % of cases, including obstetricians certified as MD geneticists (14.6 %) and MD geneticists with other specialties (0.9 %), and by obstetricians and nurse/midwives or CGC's for the remaining 2.0 %. Although the obstetrician alone provided genetic counseling for almost half (49.4 %) of abnormal results, MD geneticists (23.6 %), including obstetricians certified as MD geneticists (18.0 %) and MD geneticists with other specialties (5.6 %), and referrals to other professional facilities that have an MD geneticist and/or CGC (23.6 %) combined to provide genetic counseling for most of the remaining abnormal cases. Obstetricians with CGC provided genetic counseling for only 3.4 % of abnormal cases (Table 2) .
With regards to the amount of time spent in genetic counseling (Table 3) , 57.3 % spent less than 10 min for pre-amniocentesis genetic counseling. For discussion of the chromosome results, 88.3 % spent less than 10 min when informing patients of normal results compared with 69.7 % who spent ≥10 min for abnormal results. Respondents who spent more time in genetic counseling, ≥10 min for preamniocentesis (38.8 %) or ≥20 min for abnormal results (41.6 %), were significantly correlated with hospitals that submitted over ten specimens annually (p<0.001, p=0.001), MD geneticists (p=0.001, p<0.001), and facilities with more than three full-time obstetricians (p=0.033, p=0.012) ( Table 4) . Respondents who spent ≥5 min discussing normal results (47.5 %) were more likely to have an understanding of the JSOG guideline for prenatal testing (p=0.021), to be MD geneticists (p=0.017), or to have over 15 years experience providing such information (p=0.046) ( Table 4) .
The survey questions regarding difficulties experienced with discussion of amniocentesis results were completed by 12/103 (11.7 %) of respondents with normal results and 25/89 (28.1 %) with abnormal results. Responses were grouped based on respondent experiences of normal versus abnormal results and content areas specific to each type of test result were evaluated (Table 5 ). All respondents encountered difficulties when pregnant women lacked an understanding of the limitations of chromosome analysis with normal results. For normal results, 25.0 % reported a dilemma regarding disclosure of fetal sex when the woman expressed a strong desire to know. Based on the 2007 JSOG guideline for prenatal testing, except for prenatal diagnosis for a severe X-linked disorder, gender of the fetus should not be disclosed. For abnormal results, 60.0 % expressed genetic counseling difficulties regarding the prognosis for abnormal results, and 20.0 % had dilemmas related to a discussion of abortion. These were followed by recurrence risk (16.0 %), limitations of chromosome analysis (8.0 %), and the limited amount of time for decision making due to the advanced gestational age at time of results disclosure (8.0 %). Figure 1 shows the respondents' answers regarding the employment opportunity for CGC at clinical practices offering amniocentesis for prenatal diagnosis. Among the 103 respondents, 93(90.3 %) were familiar with CGC, and 54 (58.1 %) indicated that CGC have an essential role in providing information regarding prenatal testing. Among the ten respondents who answered that they were not familiar with CGC, two indicated that such professionals would provide a critical role in clinical practices offering amniocentesis for prenatal diagnosis. In total, 56 of the 103 respondents (54.2 %) indicated that CGC have an essential role in clinical practice. Examining the factors that correlate with these 56 respondents revealed that those less than 50 years old and hospitals that submitted more than ten specimens annually were significantly correlated factors (p=0.002, p=0.013) ( Table 6 ). Among the 56 respondents who indicated that CGC have an essential role, 41 respondents (73.2 %) did not support the employment of CGC. The reasons for these negative attitudes toward CGC employment included: the practice had a small number of amniotic fluid samples and few abnormal results (65.9 %), patients were referred to a facility with an MD geneticist and/or CGC as needed (34.1 %), lack of understanding of the CGC role at hospitals (17.1 %), and the high cost for genetic counseling service (9.8 %). Since some respondents provided more than one reason, total responses were over 100 %. The remaining 15 (26.8 %) answered that they already employ CGC or want to employ CGC. Among the positive responses that supported CGC employment or employed a CGC, more were likely to have come from hospitals that submitted more than ten specimens annually (p<0.0001), university hospitals (p<0.0001), and MD geneticists (p=0.020) ( Table 7) .
Discussion
The guidelines of the JSOG and the GMRS including JSHG and JSGC recommend that pregnant women undergoing prenatal genetic testing should receive genetic counseling (JSOG 2007; GMRS 2003) . However, the current study showed that the majority of genetic counseling regarding amniocentesis and subsequent results was provided by the obstetrician alone with limited time in genetic counseling. Most respondents spent <10 min for pre-amniocentesis genetic counseling and to discuss normal results, and <20 min for abnormal results, with limited involvement of CGC's. These findings might be attributed to the limited recognition of the importance of genetic counseling in obstetric practices offering prenatal genetic testing.
In examining who provided the genetic counseling, most genetic counseling was provided by the obstetrician alone in all situations, including pre-amniocentesis genetic counseling, discussion of normal results, and reporting of abnormal results. For abnormal fetal chromosome results, genetic counseling was more likely to be performed by MD geneticists or a referral was made to facilities that have an MD geneticist and/or CGC having more expertise regarding prenatal diagnostic testing. In this study, the most frequently reported difficulty that the respondents encountered in genetic counseling of abnormal cases involved providing information regarding prognosis for the abnormal result. Thus, for smaller facilities that do a small number of amniocentesis procedures without an MD geneticist, it is reasonable to refer pregnant women with abnormal results to the genetic professionals at large facilities. Establishing the coordination with such professional facilities enables the obstetricians to refer the pregnant women with abnormal results within the limited time frame of prenatal diagnosis. This would be especially important for abnormal results, since information about prognosis is essential for women to make informed decisions regarding whether or not to continue a pregnancy.
With regards to the amount of time spent in genetic counseling, over 50 % spent <10 min for pre-amniocentesis, over 80 % spent <10 min for a discussion of normal results, and over 50 % spent <20 min for reporting abnormal results. This suggests that these respondents more likely provided information-giving consultations, rather than genetic counseling. MD geneticists spent more time in providing counseling compared to obstetricians in all situations. Therefore, the amount and the quality of the information provided by MD geneticists could be different from that provided by others. An additional survey that would examine the specific information provided to pregnant women by providers of genetic counseling would allow us to evaluate this assumption. This differentiation by genetic counseling providers is important since most women prefer to be fully informed regarding prenatal testing with unbiased, comprehensive information delivered in a timely manner that supports the decision making process (Bhogal and Brunger 2010) . The variations in the amount and quality of genetic counseling could be due to unequal knowledge about the importance of genetic counseling in obstetric practice. Interestingly, for genetic counseling regarding normal fetal chromosome results, understanding of the JSOG guideline for prenatal testing, and having more experience providing prenatal chromosome results were significantly correlated with respondents who spent more time in genetic counseling. This suggests that these respondents recognize the importance of genetic counseling for normal results may be providing information regarding the limitations of chromosome analysis based upon their understanding of the guidelines and their clinical experience. Additionally, an understanding of the JSOG guidelines was one of the significant correlating factors regarding spending more time in genetic counseling for abnormal results. These data suggest that these respondents understand Fig. 1 Familiarity with CGC and employment opportunities at clinical practices offering amniocentesis for prenatal diagnosis the importance of the interaction with pregnant women discussing the issues of abnormal results. Therefore, information discussed with pregnant women should be further explored to support these assumptions. Such exploration might show that education of obstetricians in Japan regarding prenatal diagnosis, as listed in the JSOG guideline, could promote the understanding of the importance of genetic counseling in the clinical practice of medicine. It is conceivable that offering amniocentesis could be recognized as a genetic service, not an obstetric service. Our study found that few CGC were involved in all genetic counseling situations for fetal chromosome analysis, 0.0 % for pre-amniocentesis, 3.4 % of abnormal results and 1.0 % of normal results. These data reveal that most of the CGC's in Japan are not involved with prenatal genetic testing. The lack of the recognition of the skills and the role of CGC could be one of the reasons why there are few opportunities for CGC to make a significant contribution in obstetric practice. In fact, our study showed that although the vast majority of respondents in this study were familiar with CGC, 40 % of them indicated that CGC do not have an essential role in their clinical practice. CGC possess the skills that would allow them to provide information about prenatal testing and to support informed decision making (Farrelly et al. 2012) . Additionally, comprehensive genetic risk assessment by CGC improves the detection of identifiable genetic risk factors that may indicate the fetus is at risk for a genetic disorder (Cutillo et al. 2002; Koscica et al. 2001) . Thus, CGC are genetic professionals serving a significant role in prenatal genetic counseling. Therefore, reasons why some obstetricians would not support CGC as an integral part of their service should be further explored to consider the appropriate involvement of CGC at a clinical practice offering prenatal genetic testing in Japan.
Another reason why there is little involvement of CGC in prenatal genetic testing in Japan might be attributed to obstetricians who may recognize the essential role of CGC but do not employ CGC. In this study, over 70 % of respondents who consider CGC to have an essential role did not employ CGC due to their small amniocentesis procedure volumes and few abnormal results. In addition, they often had access to refer patients to a facility with an MD geneticist and/or CGC, as needed. These findings reflect that amniocentesis procedures are performed at various practice settings with varying numbers of procedures, from less than 10 to greater than 100 in a year. Additionally, some obstetricians answered that they did not employ CGC due to financial considerations, although they recognized the need for CGC in clinical practice. The reason why they have financial concerns could be due to the healthcare system in Japan, universal health insurance coverage. Although this system provides healthcare services with Japanese patients accepting responsibility for 30 % of these costs while the government pays the remaining 70 %, genetic counseling is not incorporated into this healthcare system. Therefore, the hospitals request private compensation for genetic counseling for their patients. If genetic counseling is incorporated into the universal health insurance coverage, it might allow the hospitals which have financial responsibility for the employment of CGC to have CGC in their clinical practice. This might lead to the establishment of the appropriate involvement of CGC in prenatal genetic counseling and reconstruct the utilization of prenatal diagnosis from a part of obstetric medicine to an indispensable part of genetic medicine.
Some obstetricians indicated that CGC have an essential role in the obstetric practices offering amniocentesis. Data analysis in this study found that this attitude was statistically significantly correlated with obstetricians less than 50 years old with over ten amniocentesis procedures in a year. These data suggest that the role of CGC is more likely to be well recognized and accepted by younger obstetricians. Interestingly, hospitals with over 30 specimens submitted annually were not significantly correlated. In these hospitals, there were more than two MD geneticists, more than three full-time obstetricians, and the respondent was an MD geneticist. This finding suggests that they might have more time to spend with pregnant women and have high skill-sets obtained through their experiences. Therefore, they might determine that they can deal with all the issues related to genetic counseling by themselves without utilizing CGC's and don't consider CGC have an essential role at their practice. However, respondents at hospitals submitting over 30 specimens annually had a statistically significant correlation to employ a CGC. These findings suggest that although they don't consider CGC to have an essential role, they need the help of CGC at their clinical practice to reduce the burden of their work or to improve the quality of genetic counseling services for pregnant women. Other significant factors which correlated with a positive response for CGC employment were respondents working at a university hospital, to be an MD geneticist, and perform over ten amniocentesis procedures in a year. The employment of CGC at large facilities performing more amniocentesis procedures would provide opportunities for CGC to work with MD geneticists and thereby expand access to professionals with the appropriate skills set in obstetric practice.
Study Limitations
One of the limitations of the present study involved extrapolating the study findings to the general population. Since the survey was only sent to clients of LabCorp Japan, the results may not be representative of all hospitals providing amniocentesis in Japan. Based on the number of amniotic fluid specimens that were received in 2009 and the Sasaki et al. (2011) reported volume of 13,000 women who had amniocentesis in 2008, our study population accounted for about a third of all specimens in Japan. Additionally, since the surveys were anonymous, we were unable to recognize who did or did not return the questionnaire to us, and therefore, follow-up contact was not performed. As a result, only 37.2 % (103) of the LabCorp Japan clients returned the surveys. Since the surveys were anonymous, it was not possible to estimate the total number of amniotic fluid specimens submitted by the 103 clients who responded to the survey. Nonetheless, we believe this is the first Japanese study to explore the provision of pre-and post-amniocentesis genetic counseling to pregnant women. Therefore, our findings provide a helpful description of the current practice. Although statistically significant differences were noted regarding the amount of time spent in genetic counseling, another limitation of the current study involved the questionnaire. This instrument was not designed to examine the specific information provided to the pregnant women or the context of discussions in each genetic counseling setting. However, the amount of time spent in genetic counseling might indicate a recognition of the importance of providing information to the pregnant women.
This study did not evaluate individual pregnant women's decisions or their understanding of the information provided during genetic counseling. Because genetic counseling should help pregnant women understand the testing and facilitate informed decision making, future studies should evaluate a pregnant woman's comprehension following genetic counseling in order to explore the appropriate information that should be provided during genetic counseling. Moreover, the practice of genetic counseling targets the decision-making process, not decision outcome (Farrelly et al. 2012) . Therefore, future studies should also evaluate the pregnant woman's satisfaction with the delivery of information in helping her to make an informed decision.
Conclusion
In order for pregnant women to make informed decisions regarding amniocentesis for fetal chromosome analysis, they should be provided with accurate and clear information about the risks, benefits and limitations of testing. While this study showed that obstetrician alone in Japan currently provide pregnant women with information regarding prenatal genetic testing, they spend limited time in genetic counseling and are more likely to refer pregnant women with abnormal fetal chromosome results to genetics professionals. The limited genetic counseling available in Japan creates potential opportunities for expanding the use of CGC.
